Get the Stockscreener App
1.055
1.44%
0.015
After Hours:
1.07
0.015
+1.42%
Jupiter Neurosciences Inc stock is traded at $1.055, with a volume of 59,938.
It is up +1.44% in the last 24 hours and down -7.46% over the past month.
Jupiter Neurosciences Inc is a clinical-stage research and development pharmaceutical company located in Jupiter, Florida. The company has developed a resveratrol platform product that targets the treatment of neuro-inflammation. Its platform product, JOTROL, offers potential therapeutic benefit to the majority of central nervous system diseases such as Alzheimer's disease, ataxias, and metabolic disorders such as Lysosomal Storage Disorders and mitochondrial diseases.
See More
Previous Close:
$1.04
Open:
$1.04
24h Volume:
59,938
Relative Volume:
0.61
Market Cap:
$36.32M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-11.96
EPS:
-0.0882
Net Cash Flow:
-
1W Performance:
-2.23%
1M Performance:
-7.46%
6M Performance:
-36.06%
1Y Performance:
-87.94%
1-Day Range:
$0.9801
$1.08
1-Week Range:
$0.9147
$1.1018
52-Week Range:
$0.51
$9.35
Jupiter Neurosciences Inc Stock (JUNS) Company Profile
Name
Jupiter Neurosciences Inc
Sector
Industry
Phone
(561) 406-6154
Address
1001 NORTH US HWY 1, JUPITER
Compare JUNS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JUNS
Jupiter Neurosciences Inc
|
1.055 | 35.80M | 0 | 0 | 0 | -0.0882 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Jupiter Neurosciences Inc Stock (JUNS) Latest News
Jupiter Neurosciences expands equity financing through SEPA advances - MSN
What margin trends mean for Jupiter Neurosciences Inc. stockInflation Impact on Stocks & Small Investment Big Gains - bollywoodhelpline.com
Jupiter Neurosciences Expands Equity Financing Through SEPA Advances - TipRanks
Jupiter Neurosciences Signs Multiple Material Agreements - TradingView — Track All Markets
Join Jupiter Neurosciences’ Exclusive Live Investor Webinar and Q&A Session on January 6 - marketscreener.com
The best and worst-performing stocks of 2025 | 2025-12-22 | Investing News - Stockhouse
Jupiter Neurosciences Shareholders Approve Key Governance Measures - TipRanks
The best and worst-performing stocks of 2025 - MSN
New Highs: What margin trends mean for Jupiter Neurosciences Inc. stockJuly 2025 Gainers & Community Verified Trade Signals - moha.gov.vn
Stock Analysis: What margin trends mean for Jupiter Neurosciences Inc. stockMarket Sentiment Review & AI Enhanced Market Trend Forecasts - Улправда
Will Jupiter Neurosciences Inc. stock sustain high P E ratiosEarnings Performance Report & Technical Pattern Based Signals - Улправда
Will Jupiter Neurosciences Inc. stock benefit from AI adoptionStop Loss & Daily Growth Stock Investment Tips - DonanımHaber
Can Jupiter Neurosciences Inc. stock maintain growth trajectoryMarket Sentiment Review & Low Risk High Win Rate Picks - Улправда
Why Jupiter Neurosciences Inc. stock remains on buy listsQuarterly Trade Review & Stepwise Trade Execution Plans - Улправда
Fed Meeting: Can Jupiter Neurosciences Inc. stock maintain growth trajectoryJuly 2025 Rallies & Reliable Entry Point Trade Alerts - Улправда
Will Jupiter Neurosciences Inc. stock split again soon2025 Trade Ideas & Weekly Consistent Profit Watchlists - Улправда
Jupiter Neurosciences Achieves Regulatory and Commercial Milestones in First Year as Public Company - citybuzz -
From FDA Clearance To The Launch Of A Consumer Line, Jupiter Neurosciences Hit Milestones In 2025; More On The Horizon | Corporate - EQS News
From FDA Clearance To The Launch Of A Consumer Line, Jupiter Neurosciences Hit Milestones In 2025; More On The Horizon - NewMediaWire
$50B+ Longevity Opportunity: Jupiter Neurosciences CEO Christer Rosen & President Alison Silva, Live at Nasdaq - Yahoo Finance
Jupiter Neurosciences Marks Transformational First Year as - GlobeNewswire
Why Jupiter Neurosciences Inc. stock attracts global investorsWeekly Profit Summary & Daily Chart Pattern Signals - Newser
Jupiter Neurosciences Marks Transformational First Year as a Public Company, Entering 2026 with Powerful Clinical and Commercial Momentum - Yahoo Finance
Jupiter Neurosciences (NASDAQ: JUNS) to Join NobleCon21 Emerging Growth Equity Conference - Stock Titan
Published on: 2025-11-27 23:20:01 - moha.gov.vn
Jupiter Neurosciences files rospectus related to resale of up to 10 million shares of our common stock by selling stockholder - marketscreener.com
Jupiter Neurosciences Inc Stock Analysis and ForecastPortfolio Diversification Tips & Watch Expert Picks Before They Rally - earlytimes.in
How Jupiter Neurosciences Inc. stock reacts to global recession fearsTrade Analysis Report & Expert Verified Stock Movement Alerts - newser.com
Will Jupiter Neurosciences Inc. stock deliver shareholder valueJuly 2025 Market Mood & Low Risk Investment Opportunities - newser.com
How Jupiter Neurosciences Inc. stock benefits from strong dollar2025 Pullback Review & Pattern Based Trade Signal System - newser.com
Is Jupiter Neurosciences Inc. stock overvalued by current metricsIndex Update & Weekly Breakout Stock Alerts - newser.com
A activity2025 Key Highlights & High Accuracy Buy Signal Tips - newser.com
Why hedge funds are buying Jupiter Neurosciences Inc. stockGlobal Markets & Free Reliable Trade Execution Plans - newser.com
Is Jupiter Neurosciences Inc. stock safe for conservative investorsProfit Target & Consistent Return Investment Signals - newser.com
Will Jupiter Neurosciences Inc. stock continue dividend increasesJuly 2025 Sector Moves & Risk Managed Trade Strategies - newser.com
Jupiter Neurosciences Inc Stock (JUNS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):